Affiliations 

  • 1 Department of Pathology and Biomedical Science, University of Otago, Christchurch, 8140, New Zealand
  • 2 Department of Pathology and Biomedical Science, University of Otago, Christchurch, 8140, New Zealand; Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
  • 3 School of Biological Sciences, University of Canterbury, Christchurch, New Zealand
  • 4 School of Biological Sciences, University of Canterbury, Christchurch, New Zealand; Bio21 Molecular Science and Biotechnology Institute, Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, 3010, Australia
  • 5 Department of Pathology and Biomedical Science, University of Otago, Christchurch, 8140, New Zealand. Electronic address: martin.kennedy@otago.ac.nz
Biochimie, 2020 Aug 14.
PMID: 32805304 DOI: 10.1016/j.biochi.2020.07.022

Abstract

Next generation DNA sequencing and analysis of amplicons spanning the pharmacogene CYP2D6 suggested that the Nextera transposase used for fragmenting and providing sequencing priming sites displayed a targeting bias. This manifested as dramatically lower sequencing coverage at sites in the amplicon that appeared likely to form G-quadruplex structures. Since secondary DNA structures such as G-quadruplexes are abundant in the human genome, and are known to interact with many other proteins, we further investigated these sites of low coverage. Our investigation revealed that G-quadruplex structures are formed in vitro within the CYP2D6 pharmacogene at these sites, and G-quadruplexes can interact with the hyperactive Tn5 transposase (EZ-Tn5) with high affinity. These findings indicate that secondary DNA structures such as G-quadruplexes may represent preferential transposon integration sites and provide additional evidence for the role of G-quadruplex structures in transposition or viral integration processes.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.